Effects of Highly Active Anti-Retroviral Therapy (HAART) on metabolite levels.
DEC-NET Serial number GB278
Published online07/07/2004 14.13.00
Last updated02/08/2005 14.04.05
Other protocol ID numberN0241128277
This trial has been approved by an ethics committee
Current trial statusOpen (actively recruiting new participants)
Major Disease
(ICD9 class)		HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
Experimental drug
Anti-retoviral therapy
GenderBoth
Age (range)2 -18

Eligibility criteria
Inclusion criteria
Children in the paediatric HIV clinic over past 2.5 years.
Exclusion criteria
none

Trial design/methodology
Phase0
Kind of studySafety
Pharmacokinetics
DesignRetrospective analysis
Purpose of study
Assessment of the effects of highly active anti-retroviral therapy (HAART) on certain metabolite levels in children attending the paediatric HIV clinic over past 2.5 years, and determination of the proportion of children with HIV infection in which they occur.
Primary outcomes
Metabolite ranges, including: otal cholesterol, high density lipid (HDL), cholesterol/HDL ratio, low density lipid (LDL), triglyceride (TG), lactate and glucose levels.
Summary of study design, objectives, and ongoing research findings
Retrospective analysis of routine metabolic tests from children in the paediatric HIV clinic over past 2.5 years.
Principal investigator
NameDr Hermione Lyall
InstitutionSt Mary's Hospital
Postal addressPaediatrics HIV/AIDS, QEQM Wing, St Mary's Hospital, Praed Street, London, W2 1NY
CityLondon
CountryUNITED KINGDOM
Phone020 7886 6095
Fax
E-mailh.lyall@Ic.ac.uk


Sponsor name
Unknown (Unknown)

ISRCTN  EudraCT